Expression Of Soluble LAG-3Molecule In Sera From Gastric Cancer Patients And Its Clinical Implications

Objective To investigate the serum soluble LAG-3(soluble LAG-3，sLAG-3) level ingastric cancer patients and its clinical implications.Methods The sLAG-3levels in sera from92cases of gastric cancer patients,50cases of healthydonors were detected by ELISA. Clinical implications were also analyzed. The diagnostic value ofsLAG-3as a marker for gastric cancer diagnosis was assessed by ROC curve. The CEA levels in thespecimen was detected and compared with sLAG-3for the efficiency of diagnosis. LAG-3expression inboth gastric cancer and adjacent normal tissues was detected by immunohistochemisrry methods.Results The median LAG-3level in sera of gastric cancer was137.06(1551.09) ng/mL,significantly lower than711.43(1897.56) ng/mL of healthy donors(Z=7.513,P<0.01). The sLAG-3level in sera from gastric cancer patients was positively correlated to stage、differentiation and depth ofinvasion(all P <0.05), while it was not correlated to any other clinicopathological parameters. Thesensitivity and accuracy of sLAG-3for gastric cancer diagnosis were75.00%and81.69%respectively,both higher than16.30%and43.66%of CEA. We also verified that the expression of LAG-3could be detected in gastric cancer tissues as well as adjacent normal tissues, respectively.Conclusion sLAG-3may be regarded as a candidate serum marker for gastric cancer diagnosis.